A Variant of the Glucose Transporter Gene SLC2A2 Modifies the Glycaemic Response to Metformin Therapy in Recently Diagnosed Type 2 Diabetes

Diabetologia - Germany
doi 10.1007/s00125-018-4759-z
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Baseline Characteristics in the VERIFY Study: A Randomized Trial Assessing the Durability of Glycaemic Control With Early Vildagliptin-Metformin Combination in Newly Diagnosed Type 2 Diabetes

Diabetic Medicine
Internal MedicineEndocrinologyMetabolismDiabetes
2019English

Pronounced Reduction of Cutaneous Langerhans Cell Density in Recently Diagnosed Type 2 Diabetes

Diabetes
Internal MedicineEndocrinologyMetabolismDiabetes
2013English

Empagliflozin and Metformin Combination Therapy in Type 2 Diabetes Mellitus

International Journal of Basic and Clinical Pharmacology
2015English

A Randomized, Open Label, Comparative Study of Biotin as an Add-On Therapy to Metformin vs Metformin Alone in Newly Diagnosed Type 2 Diabetes Mellitus Patients

IOSR Journal of Dental and Medical Sciences
2016English

Paradoxical Glycaemic Response to Surgical Treatment of Ovarian Hyperthecosis in a Patient With Type 2 Diabetes

British Journal of Diabetes and Vascular Disease
Internal MedicineCardiologyEndocrinologyCardiovascular MedicineMetabolismDiabetes
2015English

Evolutionary Structural and Functional Conservation of an Ortholog of the GLUT2 Glucose Transporter Gene (SLC2A2) in Zebrafish

American Journal of Physiology - Regulatory Integrative and Comparative Physiology
Physiology
2009English

Early Glycaemic Control in Metformin Users Receiving Their First Add-On Therapy: A Population-Based Study of 4,734 People With Type 2 Diabetes

Diabetologia
Internal MedicineEndocrinologyMetabolismDiabetes
2015English

Sodium-Glucose Co-Transporter-2 Inhibitors in Type 1 Diabetes—a Dangerous Ally

US Endocrinology
EndocrinologyMetabolismDiabetes
2017English

Empagliflozin: A New Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes

Drugs in Context
Molecular MedicinePharmacology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy